A single dose of dapagliflozin, an SGLT-2 inhibitor, induces higher glycosuria in GCK- and HNF1A-MODY than in type 2 diabetes mellitus

AIMS: SGLT2 inhibitors are a new class of oral hypoglycemic agents used in type 2 diabetes (T2DM). Their effectiveness in maturity onset diabetes of the young (MODY) is unknown. We aimed to assess the response to a single dose of 10 mg dapagliflozin in patients with Hepatocyte Nuclear Factor 1 Alpha...

Descripción completa

Detalles Bibliográficos
Autores principales: Hohendorff, J., Szopa, M., Skupien, J., Kapusta, M., Zapala, B., Platek, T., Mrozinska, S., Parpan, T., Glodzik, W., Ludwig-Galezowska, A., Kiec-Wilk, B., Klupa, T., Malecki, M. T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5511327/
https://www.ncbi.nlm.nih.gov/pubmed/28593615
http://dx.doi.org/10.1007/s12020-017-1341-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5511327/
https://www.ncbi.nlm.nih.gov/pubmed/28593615
http://dx.doi.org/10.1007/s12020-017-1341-2

Ejemplares similares